GV20 Therapeutics | ApexOnco - Clinical Trials news and analysis

x

“The team is super responsive to my inquiries and suggestions”

Chief Business Officer

US public biotech company

Click here for more information

Conferences

22 July 2024

ESMO 2024 preview – Summit and BioNTech battle again

The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.

Subscribe to GV20 Therapeutics